Bacterial detection is vital to sustain healthy living.
Preventing bacterial contamination is key. We produce bacterial detection solutions, reliable, affordable, easy and fast.
Detact Diagnostics™, founded in 2014, developed a novelle and disruptive bacterial detection platform/technique (and patented is) that is truly innovative, highly sensitive, specific and fast (seconds - minutes) that lends itself to application development in healthcare and food.
Joost was trained as a European Certified Trauma Surgeon, received his PhD in collaboration with University of Pennsylvania, and left the clinical field to found Detact Diagnostics, of which he is the current fulltime CEO as well as the R&D team leader.
The management and research team is very experienced in the fields of medicine, surgery, clinical chemistry, microbiology, chemical engineering, patent law and all commercial aspects of bringing diagnostic tests to market.
“Identifying bacterial presence on site enables healthcare providers and the food processing industry to be pro-active and prevent an outbreak rather than deal with the consequence of after the fact. Detecting harmful bacteria with a quick-test would reduce the likelihood of an outbreak” (Joost Gazendam, CEO Detact Diagnostics).
"Current global bacterial detection market is estimated at $ 1.4 Billion/year in just healthcare and estimated to grow to exceed $ 4 Billion/year by 2022 in the combined ﬁeld of healthcare and food safety" (Tom de Poorter, COO Detact Diagnostics).
"We are confident in this technology and are excited to be a part of this opportunity as it will truly assist hospitals in their ability to provide safe environments for their patients" (Gregory L. Biggs, CEO Li-COR, USA).
"We were eager to invest in Detact, not only because of the worldwide problems it addresses with an innovative product, but also because of the inventions it has to collaborate with strategic partners in order to expedite the implementation of this concept in the international healthcare industry.” (Geert Buiter, Executive VP, Investment group NOM, The Netherlands)
European Regional Development Fund (ERDF) has allocated funds to the region of the Northern Netherlands, consisting of the provinces of Friesland, Groningen and Drenthe. These funds, in combination with additional public and private co-financing, will strengthen the region’s potential for research and innovation.
SNN supports the development of our innovative technology with project subsidies for the development of the Milk-protease test and a quick E.Coli test.
The Site and its original content, features, and functionality are owned by Detact Diagnostics™ and are protected by international copyright, trademark, patent, trade secret, and other intellectual property or proprietary rights laws.